Ameriprise Financial Inc. cut its position in shares of Humana Inc. (NYSE:HUM) by 6.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 946,236 shares of the insurance provider’s stock after selling 65,418 shares during the period. Ameriprise Financial Inc. owned approximately 0.63% of Humana worth $195,024,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of HUM. Howard Hughes Medical Institute raised its position in shares of Humana by 6.2% in the first quarter. Howard Hughes Medical Institute now owns 1,178 shares of the insurance provider’s stock worth $243,000 after buying an additional 69 shares in the last quarter. Sit Investment Associates Inc. raised its position in shares of Humana by 0.6% in the third quarter. Sit Investment Associates Inc. now owns 13,510 shares of the insurance provider’s stock worth $2,390,000 after buying an additional 80 shares in the last quarter. Wetherby Asset Management Inc. raised its position in shares of Humana by 2.6% in the first quarter. Wetherby Asset Management Inc. now owns 3,800 shares of the insurance provider’s stock worth $783,000 after buying an additional 96 shares in the last quarter. Advantus Capital Management Inc raised its position in shares of Humana by 1.0% in the third quarter. Advantus Capital Management Inc now owns 14,832 shares of the insurance provider’s stock worth $2,624,000 after buying an additional 145 shares in the last quarter. Finally, BB&T Securities LLC raised its position in shares of Humana by 10.8% in the third quarter. BB&T Securities LLC now owns 1,523 shares of the insurance provider’s stock worth $269,000 after buying an additional 149 shares in the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Shares of Humana Inc. (NYSE:HUM) traded up 0.88% during mid-day trading on Friday, hitting $234.46. The stock had a trading volume of 2,573,810 shares. The stock has a 50-day moving average price of $230.06 and a 200 day moving average price of $213.32. The stock has a market cap of $33.84 billion, a P/E ratio of 23.90 and a beta of 0.90. Humana Inc. has a 52 week low of $150.00 and a 52 week high of $236.35.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, May 3rd. The insurance provider reported $2.75 EPS for the quarter, topping the consensus estimate of $2.55 by $0.20. The firm had revenue of $13.76 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 2.71% and a return on equity of 14.38%. During the same quarter last year, the firm posted $1.86 EPS. On average, equities analysts forecast that Humana Inc. will post $11.15 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Investors of record on Friday, June 30th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.60 annualized dividend and a yield of 0.68%. Humana’s dividend payout ratio (DPR) is presently 16.24%.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/06/16/ameriprise-financial-inc-reduces-stake-in-humana-inc-hum-updated-updated-updated.html.

A number of research analysts have weighed in on the company. BidaskClub lowered Humana from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $255.00 price target on the stock in a research note on Tuesday. Argus raised Humana from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a research note on Friday, June 9th. Morgan Stanley initiated coverage on Humana in a report on Tuesday, June 6th. They set an “overweight” rating and a $262.00 price objective for the company. Finally, Royal Bank of Canada restated a “hold” rating and set a $214.00 price objective on shares of Humana in a report on Monday, June 5th. Eight investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $223.16.

In related news, CEO Bruce D. Broussard sold 118,231 shares of Humana stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $225.82, for a total value of $26,698,924.42. Following the transaction, the chief executive officer now owns 171,170 shares in the company, valued at approximately $38,653,609.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jody L. Bilney sold 4,348 shares of Humana stock in a transaction on Tuesday, March 21st. The stock was sold at an average price of $213.80, for a total transaction of $929,602.40. Following the completion of the transaction, the senior vice president now owns 13,578 shares in the company, valued at approximately $2,902,976.40. The disclosure for this sale can be found here. Insiders sold a total of 142,618 shares of company stock worth $32,183,465 in the last quarter. Insiders own 0.80% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.